. 2007 Apr 12;98(6):767–771. doi: 10.1111/j.1349-7006.2007.00455.x

Table 1.

Summary of adjuvant trastuzumab trials

Study	Investigational treatment	Control treatment	n	HR for DFS (95% CI)	P‐value
Romond et al.⁽ ¹⁸ ⁾	AC→PH	AC→P	3351	0.48 (0.39–0.59)	2 × 10⁻¹²
Piccart‐Gebhart et al.⁽ ¹⁷ ⁾	Chemotherapy→H	Chemotherapy	3387	0.54 (0.43–0.67)	<0.0001
Slamon et al.⁽ ¹⁹ ⁾	AC→TH	AC→T	3222	0.49 (0.37–0.65)	4.8 × 10⁻⁷
Slamon et al.⁽ ¹⁹ ⁾	TCH			0.61 (0.47–0.79)	0.00015
Joensuu et al.⁽ ²⁰ ⁾	TH→CEF	T→CEF	232	0.46 (0.21–0.83)	0.0078
Joensuu et al.⁽ ²⁰ ⁾	VH→CEF	V→CEF

AC, doxorubicin and cyclophosphamide; CEF, cyclophosphamide, epirubicin and 5‐fluorouracil; CI, confidence interval; DFS, disease‐free survival; H, trastuzumab; HR, hazard ratio; P, paclitaxel; T, docetaxel; TCH, docetaxel, carboplatin, and trasuzumab; V, vinorelbine.